Tarceva News and Research

RSS

Tarceva is a drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Tarceva is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called CP-358,774, erlotinib, erlotinib hydrochloride, and OSI-774.

Cancer Research UK and AstraZeneca announce innovative deal for promising anti-cancer compound

Cancer Research UK and Cancer Research Technology (CRT) - the charity's development and commercialisation arm - today announced an innovative new arrangement to progress into clinical development a potential anti-cancer compound from AstraZeneca.

19 May 2008

Cancer stem cells may be at the root of brain tumors

Stem cells -- popularly known as a source of biological rejuvenation -- may play harmful roles in the body, specifically in the growth and spread of cancer. Amongst the wildly dividing cells of a tumor, scientists have located cancer stem cells.

27 Dec 2007

Positive results for novel anti-cancer drug ECO-4601

Researchers report positive results from a Phase I/II clinical trial of a novel anti-cancer drug which offers two modes of action.

24 Oct 2007

DNA microarray chips improved therapy in some patients with incurable cancer

Like many oncologists, Eric P. Lester, M.D., was faced with a dilemma: seven patients with advanced, incurable cancer, an arsenal of drugs that may or may not help them, and not enough solid proof about treatment efficacy to guide him.

20 Sep 2007

Study suggests brain tumors need treatment with multiple 'targeted' drugs

Researchers at Dana-Farber Cancer Institute have shown that several, rather than just one, cell-growth switches are simultaneously overactive in many brain tumors and other solid tumors, explaining why treatment with just a single "targeted" switch-blocking drug often yields disappointing results.

13 Sep 2007

Lung cancer patients taking Tarceva who develop a rash fair better

The appearance of a rash in cancer patients treated with erlotinib (Tarceva) is strongly associated with longer survival, according to researchers from the drug's developer, OSI Pharmaceuticals, Inc.

4 Jul 2007

Skin rash actually signifies better outcomes for pancreatic and lung cancer patients

The appearance of a rash in cancer patients treated with erlotinib (Tarceva) is strongly associated with longer survival, according to researchers from the drug's developer, OSI Pharmaceuticals, Inc.

3 Jul 2007

Guidelines on skin reactions to Epidermal Growth Factor Receptor Inhibitors (EGFRIs)

Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach , usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of "The Oncologist."

24 May 2007

Britain second rate when it comes to treating cancer sufferers

When it comes to accessing the best drugs for cancer Britain is a second rate country to be sick in.

14 May 2007

Tarceva extends life of patients with pancreatic cancer

New results published by the Journal of Clinical Oncology show that adding Tarceva (erlotinib) to gemcitabine chemotherapy significantly improves survival by 22 percent in patients with advanced pancreatic cancer.

27 Apr 2007

New mechanism identified for resistance to targeted lung cancer drugs

An international research team, led by investigators from the Massachusetts General Hospital (MGH) Cancer Center and Dana-Farber Cancer Institute (DFCI), has found a new way that some lung tumors become resistant to treatment with targeted therapy drugs like Iressa and Tarceva.

27 Apr 2007

New methods for treating lung cancer cells that have become resistant to new anti-cancer agents

Researchers at the Ireland Cancer Center of University Hospitals Case Medical Center have developed methods for treating lung cancer cells that have become resistant to new anti-cancer agents.

24 Apr 2007

New test identifies patients who benefit from targeted cancer drugs

New lab test accurately identified patients who would benefit from treatment with the molecularly-targeted anti-cancer therapies gefitinib (Iressa, AstraZeneca) and erlotinib (Tarceva, Genentech).

13 Jun 2006

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

4 Jun 2006

Experimental treatment increases response rates in advanced lung cancer

An early phase study pairing an experimental targeted therapy with a common anti-inflammatory produced promising results in patients with advanced lung cancer, researchers at UCLA's Jonsson Cancer Center reported.

1 Jun 2006

Novel animal model of lung adenocarcinoma

Drs. Katerina Politi, Harold Varmus and colleagues at the Memorial Sloan Kettering Cancer Center in New York have developed a novel animal model of lung adenocarcinoma that will be of great use in testing the efficacy of targeted therapies against human lung cancer.

17 May 2006

Genzyme launches test to monitor Gleevec resistance

Genzyme Corporation has announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec (imatinib mesylate).

13 Feb 2006

Targeted cancer therapies: Another step forward

While it is clear that the treatment of cancer has already begun to undergo a paradigm shift with the inclusion of innovative targeted therapies into current regimens, it would be wrong to assume these products will entirely replace traditional chemotherapy as the standard treatment for cancer sufferers.

22 Dec 2005

Targeted cancer therapies: Another step forward

22 Dec 2005

Gene mapping project promises new targeted cancer therapies

Government researchers in the United States have this week launched a pilot project to find all the little genetic changes that cause cancer in the hope it will lead to a whole new world of targeted cancer therapy.

14 Dec 2005